Clene Inc. To Discuss CNM-Au8 Topline Data From The HEALEY ALS Platform Trial Call Transcript
And welcome to the Clene Inc. presentation of CNM-Au8 topline data from the Healey ALS Platform Trial conference call. Please note today's conference is being recorded. (Operator Instructions) At this time, I would like to turn the conference over to Rob Etherington, CEO of Clene. Mr. Etherington, you may begin your conference.
Thank you. Thank you very much. Welcome, everybody, to the Healey ALS Platform Trial results this morning. We are very grateful to have Dr. Merit Cudkowicz with us from the Healey ALS Platform Trial.
Dr. Merit Cudkowicz is the Chief of Neurology at Massachusetts General Hospital, the Director of the Sean M. Healey & AMG Centre for ALS. And she joins our Chief Medical Officer, Robert Glanzman, our Chief Development Officer, Michael Hotchkin, and myself to discuss these results.
I remind everybody of the forward-looking statement that is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |